Literature DB >> 10037517

Erbium:YAG laser resurfacing for refractory melasma.

R M Manaloto1, T Alster.   

Abstract

BACKGROUND: Melasma is a facial dyspigmentation which is a common complaint in patients with darker skin tones. Many current therapies used for this condition are ineffective and can cause significant adverse effects.
OBJECTIVE: The purpose of this study was to evaluate the role of erbium:YAG laser resurfacing in the management of refractory melasma.
METHODS: Ten female patients with melasma unresponsive to previous therapy of bleaching creams and chemical peels were included in this study. Full face skin resurfacing using an erbium: YAG laser (2.94 microm) was performed using 5.1-7.6 J/cm2 energy. Clinical evaluations using the Melasma Area and Severity Index (MASI) and melanin reflectance spectrometry measurements were taken preoperatively and at 0.5, 1, 1.5, 3, and 6 weeks and 3, 5, and 6 months postoperatively. Adverse effects after laser resurfacing such as prolonged erythema, infection, and hyperpigmentation were recorded.
RESULTS: There was marked improvement of the melasma immediately after laser surgery using the parameters outlined; however, between 3 and 6 weeks postoperatively, all patients exhibited post-inflammatory hyperpigmentation. Decreased MASI and melanin reflectance spectrometry measurement scores were noted after biweekly glycolic acid peels and at the end of 6 months, significant clinical improvement in the melasma was seen compared to the preoperative evaluation.
CONCLUSION: Erbium:YAG laser resurfacing effectively improves melasma; however, the almost universal appearance of transient post-inflammatory hyperpigmentation necessitates prompt and persistent intervention. The use of this laser therapy is recommended only for refractory melasma.

Entities:  

Mesh:

Year:  1999        PMID: 10037517     DOI: 10.1046/j.1524-4725.1999.08103.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  19 in total

Review 1.  [Lasers and aesthetic dermatology].

Authors:  A J Stratigos; J S Dover; K A Arndt
Journal:  Hautarzt       Date:  2003-06-12       Impact factor: 0.751

2.  Skin pretreatment with an Er:YAG laser promotes the transdermal delivery of three narcotic analgesics.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Chia-Lang Fang; Ching-Ru Liu; Jia-You Fang
Journal:  Lasers Med Sci       Date:  2007-03-03       Impact factor: 3.161

Review 3.  [Fractional photothermolysis: a new option for treating melasma?].

Authors:  S Karsai; C Raulin
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

4.  Laser therapy in ethnic populations.

Authors:  Patrick D Cole; Daniel A Hatef; Yoav Kaufman; Jason N Pozner
Journal:  Semin Plast Surg       Date:  2009-08       Impact factor: 2.314

5.  The Asian Problem of Frequent Laser Toning for Melasma.

Authors:  Brian Tian
Journal:  J Clin Aesthet Dermatol       Date:  2017-07-01

6.  2940-nm Er:YAG fractional laser enhanced the effect of topical drug for psoriasis.

Authors:  Ruilian Li; Jun Zhou; Hui Su; Mei Wang; Yongxian Wang; Shengxiang Xiao; Huiqun Ma
Journal:  Lasers Med Sci       Date:  2017-06-23       Impact factor: 3.161

Review 7.  Evaluation of Laser Effects on the Human Body After Laser Therapy.

Authors:  Ensieh Khalkhal; Mohammadreza Razzaghi; Mohammad Rostami-Nejad; Majid Rezaei-Tavirani; Hazhir Heidari Beigvand; Mostafa Rezaei Tavirani
Journal:  J Lasers Med Sci       Date:  2020-01-18

8.  The Split-Face Comparison of the Combined Er-YAG Laser and Hydroquinone 4% With Hydroquinone 4% Alone in the Treatment of Melasma in Iranian Patients: A Prospective, Interventional Case Study.

Authors:  Nastaran Namazi; Aida Hesami; Yasaman Ketabi
Journal:  J Lasers Med Sci       Date:  2020-01-18

9.  Lasers for treatment of melasma and post-inflammatory hyperpigmentation.

Authors:  Pooja Arora; Rashmi Sarkar; Vijay K Garg; Latika Arya
Journal:  J Cutan Aesthet Surg       Date:  2012-04

Review 10.  The use of ablative lasers in the treatment of facial melasma.

Authors:  Orlando Oliveira de Morais; Érica Freitas Lima Lemos; Márcia Carolline dos Santos Sousa; Ciro Martins Gomes; Izelda Maria Carvalho Costa; Carmen Déa Ribeiro de Paula
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.